Ronald J Wilder

US Patent:

20020168360, Nov 14, 2002

Filed:

Mar 4, 2002

Appl. No.:

10/091236

Inventors:

Christine Dingivan - Germantown MD, US
Ronald Wilder - Rockville MD, US

International Classification:

A61K039/395

US Classification:

424/143100

Abstract:

The present invention provides to methods of preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder comprising administering to a subject in need thereof one or more integrin antagonists and at least one other prophylactic or therapeutic agent. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder.

US Patent:

20040176272, Sep 9, 2004

Filed:

Jan 30, 2004

Appl. No.:

10/769720

Inventors:

Ronald Wilder - Derwood MD, US

Assignee:

MedImmune, Inc.

International Classification:

A61K038/00

US Classification:

514/002000

Abstract:

The present invention provides methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing antagonists of integrin . The present invention encompasses the use of methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy, or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing an integrin antagonist in combination with another therapy (e.g., another prophylactic or therapeutic agent). In particular, the present invention provides methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, comprising administering to a subject in need thereof at least one antagonist of integrin and at least one other therapy. The present invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating periodontal disease, or aseptic loosening of joint replacement (prostheses), Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or conditions associated therewith.

US Patent:

20050084489, Apr 21, 2005

Filed:

Mar 4, 2003

Appl. No.:

10/379145

Inventors:

Ronald Wilder - Derwood MD, US

International Classification:

A61K039/395
A61K031/66

US Classification:

424144100, 514102000

Abstract:

The present invention provides methods of preventing, treating, managing or ameliorating disorders utilizing an integrin αβantagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphosphonate. The present invention also encompasses methods of preventing, treating, managing or ameliorating disorders utilizing an integrin αβantagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphophonate, in further combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin αβantagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. In particular, the present invention provides methods of preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin αβ, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith, utilizing an antibody that immunospecifically binds to integrin αβ(e.g., VITAXIN) in combination with an HMG-CoA reductase inhibitor and/or bisphosphonate, and optionally in combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin αβantagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. The present also invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin αβ, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith.

US Patent:

20070077246, Apr 5, 2007

Filed:

Jul 11, 2006

Appl. No.:

11/485557

Inventors:

Scott Koenig - Rockville MD, US
Ronald Wilder - Rockville MD, US
Ezio Bonvini - Rockville MD, US
Leslie Johnson - Darnestown MD, US

International Classification:

A61K 39/395
A61K 38/28
C12P 21/06
C07K 16/28
A61K 38/22
C12N 5/06

US Classification:

424144100, 514003000, 514012000, 435334000, 435069100, 435320100, 530388220

Abstract:

The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-CD3 antibodies.

US Patent:

20080095766, Apr 24, 2008

Filed:

Jun 14, 2007

Appl. No.:

11/763434

Inventors:

Scott Koenig - Rockville MD, US
Ronald Wilder - Rockville MD, US
Ezio Bonvini - Rockville MD, US
Leslie Johnson - Darnestown MD, US
Stanley Pillemer - North Potomac MD, US

Assignee:

MacroGenics, Inc. - Rockville MD

International Classification:

A61K 39/395
A61P 1/00
A61P 17/06
A61P 19/02
A61P 25/00
A61P 3/10
A61P 35/00
A61P 37/06

US Classification:

424133100, 424144100, 424154100

Abstract:

The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.

US Patent:

20090053234, Feb 26, 2009

Filed:

Mar 14, 2008

Appl. No.:

12/048738

Inventors:

Christine Dingivan - Germantown MD, US
Ronald Wilder - Rockville MD, US

International Classification:

A61K 39/395
A61K 31/519
A61K 31/42
A61K 31/675
A61K 38/13
A61K 31/436
A61K 38/00
A61K 31/60
A61K 31/192
A61K 31/196
A61K 31/122

US Classification:

4241431, 514249, 514378, 514110, 514 11, 514291, 514 2, 514165, 514570, 514567, 514682

Abstract:

The present invention provides to methods of preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder comprising administering to a subject in need thereof one or more integrin αβantagonists and at least one other prophylactic or therapeutic agent. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder.

US Patent:

50063308, Apr 9, 1991

Filed:

Nov 30, 1988

Appl. No.:

7/277708

Inventors:

Esther M. Sternberg - Chevy Chase MD
Ronald L. Wilder - Rockville MD
George P. Chrousos - Bethesda MD
Philip W. Gold - Washington DC

Assignee:

The United States of America as represented by the of the Department of
Health and Human Services - Washington DC

International Classification:

A61K 4900
G01N 3100
G01N 3348

US Classification:

424 9

Abstract:

Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.

US Patent:

52099202, May 11, 1993

Filed:

Sep 25, 1989

Appl. No.:

7/412294

Inventors:

Esther M. Sternberg - Chevy Chase MD
Ronald L. Wilder - Derwood MD
Philip W. Gold - Washington DC
George P. Chrousos - Bethesda MD

Assignee:

The United States of America as represented by the United States
Department of Health and Human Services - Washington DC

International Classification:

G01N 100
G01N 3348
A61K 3760
A61K 4505

US Classification:

424 9

Abstract:

Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.